Bioequivalence of Telmione vs Micardis (Telmisartan) in Healthy Volunteers

Phase 1, randomised, open-label trial of telmisartan in hypertension (HTN) (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration (Cmax) of Telmisartan up to 72 hours and Area Under the Curve to the Last Quantifiable Concentration (AUClast) of Telmisartan up to 72 hours. Status: unknown.